淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展

doi:10.3760/cma.j.cn371439-20220531-00125

国际肿瘤学杂志 ›› 2022, Vol. 49 ›› Issue (10): 627-629.doi: 10.3760/cma.j.cn371439-20220531-00125

淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展

徐凯, 文刚(), 李瑞, 田园

安徽医科大学第三附属医院（合肥市第一人民医院）胃肠外科，合肥 230061

收稿日期:2022-05-31 修回日期:2022-06-07 出版日期:2022-10-08 发布日期:2022-12-01
通讯作者: 文刚 E-mail:wengang@medmail.com

Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms

Xu Kai, Wen Gang(), Li Rui, Tian Yuan

Department of Gastrointestinal Surgery， Third Affiliated Hospital of Anhui Medical University （First People's Hospital of Hefei）， Hefei 230061， China

Received:2022-05-31 Revised:2022-06-07 Online:2022-10-08 Published:2022-12-01
Contact: Wen Gang E-mail:wengang@medmail.com

摘要/Abstract

摘要：

肿瘤相关炎症与肿瘤的发生发展密切相关。淋巴细胞与C反应蛋白比值（LCR）是一种反映机体炎症状态的新型标志物，在预测消化系统肿瘤预后中具有重要价值。该标志物相较于单独检测淋巴细胞或C反应蛋白有着更高的敏感性和准确性，可为消化系统肿瘤的临床诊疗提供新的方向。

关键词: 淋巴细胞, C反应蛋白质, 消化系统肿瘤, 预后

Abstract:

Tumor-associated inflammation is closely related to the development of tumors. The ratio of lymphocytes to C-reactive protein （LCR） is a new marker reflecting the inflammatory state of the body， which plays an important role in predicting the prognosis of digestive system neoplasms. Compared with the detection of lymphocytes or C-reactive protein alone， this marker has higher sensitivity and accuracy， and can provide a new direction for clinical diagnosis and treatment of digestive system neoplasms.

Key words: Lymphocytes, C-reactive protein, Digestive system neoplasms, Prognosis

徐凯, 文刚, 李瑞, 田园. 淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 627-629.

Xu Kai, Wen Gang, Li Rui, Tian Yuan. Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms[J]. Journal of International Oncology, 2022, 49(10): 627-629.

参考文献 22

[1]	Suarez-Carmona M, Lesage J, Cataldo D, et al. EMT and inflammation: inseparable actors of cancer progression[J]. Mol Oncol, 2017, 11(7): 805-823. DOI: 10.1002/1878-0261.12095. doi: 10.1002/1878-0261.12095 pmid: 28599100
[2]	Khandia R, Munjal A. Interplay between inflammation and cancer[J]. Adv Protein Chem Struct Biol, 2020, 119: 199-245. DOI: 10.1016/bs.apcsb.2019.09.004. doi: S1876-1623(19)30069-0 pmid: 31997769
[3]	Yu Y, Wu Z, Shen Z, et al. Preoperative C-reactive protein-to-albumin ratio predicts anastomotic leak in elderly patients after curative colorectal surgery[J]. Cancer Biomarkers, 2020, 27(3): 295-302. DOI: 10.3233/CBM-190470. doi: 10.3233/CBM-190470 pmid: 31658046
[4]	Stojkovic Lalosevic M, Pavlovic Markovic A, Stankovic S, et al. Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer[J]. Disease Markers, 2019, 2019: 6036979. DOI: 10.1155/2019/6036979. doi: 10.1155/2019/6036979
[5]	Kamonvarapitak T, Matsuda A, Matsumoto S, et al. Preoperative lymphocyte-to-monocyte ratio predicts postoperative infectious complications after laparoscopic colorectal cancer surgery[J]. Int J Clin Oncol, 2020, 25(4): 633-640. DOI: 10.1007/s10147-019-01583-y. doi: 10.1007/s10147-019-01583-y pmid: 31781993
[6]	杨银静, 李桂香, 唐敏. 纤维蛋白原、NLR及F-NLR评分在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(7): 433-435. DOI: 10.3760/cma.j.cn371439-20201230-00083. doi: 10.3760/cma.j.cn371439-20201230-00083
[7]	Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer[J]. Ann Surg, 2020, 272(2): 342-351. DOI: 10.1097/SLA.0000000000003239. doi: 10.1097/SLA.0000000000003239 pmid: 32675548
[8]	Yildirim M, Koca B. Lymphocyte C-reactive protein ratio: a new biomarker to predict early complications after gastrointestinal oncologic surgery[J]. Cancer Biomarkers, 2021, 31(4): 409-417. DOI: 10.3233/CBM-210251. doi: 10.3233/CBM-210251 pmid: 34151845
[9]	Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage Ⅱ/Ⅲ colon cancer[J]. Ann Surg Oncol, 2020, 27(3): 844-852. DOI: 10.1245/s10434-019-07904-9. doi: 10.1245/s10434-019-07904-9
[10]	Lu L H, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study[J]. Liver Int, 2021, 41(2): 378-387. DOI: 10.1111/liv.14567. doi: 10.1111/liv.14567
[11]	Takeuchi M, Kawakubo H, Hoshino S, et al. Lymphocyte-to-C-reactive protein ratio as a novel marker for predicting oncological outcomes in patients with esophageal cancer[J]. World J Surg, 2021, 45(11): 3370-3377. DOI: 10.1007/s00268-021-06269-z. doi: 10.1007/s00268-021-06269-z pmid: 34383091
[12]	Yugawa K, Itoh S, Yoshizumi T, et al. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma[J]. Int J Clin Oncol, 2021, 26(10): 1901-1910. DOI: 10.1007/s10147-021-01962-4. doi: 10.1007/s10147-021-01962-4 pmid: 34117554
[13]	Lu LH, Wei W, Li SH, et al. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE[J]. Aging (Albany, NY), 2021, 13(4): 5358-5368. DOI: 10.18632/aging.202468. doi: 10.18632/aging.202468
[14]	Cheng CB, Zhang QX, Zhuang LP, et al. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study[J]. Jpn J Clin Oncol, 2020, 50(10): 1141-1149. DOI: 10.1093/jjco/hyaa099. doi: 10.1093/jjco/hyaa099
[15]	Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer[J]. Clin Nutr, 2020, 39(4): 1209-1217. DOI: 10.1016/j.clnu.2019.05.009. doi: S0261-5614(19)30220-1 pmid: 31155370
[16]	Angin YS, Yildirim M, Dasiran F, et al. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?[J]. ANZ J Surg, 2021, 91(7-8): 1521-1527. DOI: 10.1111/ans.16913. doi: 10.1111/ans.16913 pmid: 33956378
[17]	Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer[J]. Semin Oncol, 2011, 38(4): 552-560. DOI: 10.1053/j.seminoncol.2011.05.009. doi: 10.1053/j.seminoncol.2011.05.009 pmid: 21810514
[18]	Nakamura Y, Shida D, Boku N, et al. Lymphocyte-to-C-reactive protein ratio is the most sensitive inflammation-based prognostic score in patients with unresectable metastatic colorectal cancer[J]. Dis Colon Rectum, 2021, 64(11): 1331-1341. DOI: 10.1097/DCR.0000000000002059. doi: 10.1097/DCR.0000000000002059 pmid: 34623347
[19]	Iseda N, Itoh S, Yoshizumi T, et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma[J]. Int J Clin Oncol, 2021, 26(10): 1890-1900. DOI: 10.1007/s10147-021-01985-x. doi: 10.1007/s10147-021-01985-x pmid: 34251555
[20]	Yugawa K, Maeda T, Kinjo N, et al. Prognostic impact of lymphocyte-C-reactive protein ratio in patients who underwent surgical resection for hepatocellular carcinoma[J]. J Gastrointest Surg, 2022, 26(1): 104-112. DOI: 10.1007/s11605-021-05085-z. doi: 10.1007/s11605-021-05085-z
[21]	Zhang YF, Lu LH, Zhong C, et al. Prognostic value of the pre-operative lymphocyte-C-reactive protein ratio in hepatocellular carcinoma patients treated with curative intent: a large-scale multicentre study[J]. J Inflamm Res, 2021, 14: 2483-2495. DOI: 10.2147/JIR.S311994. doi: 10.2147/JIR.S311994
[22]	Yao WY, Wu XS, Liu SL, et al. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(3): 267-272. DOI: 10.1016/j.hbpd.2021.08.006. doi: 10.1016/j.hbpd.2021.08.006

淋巴细胞与C反应蛋白比值对消化系统肿瘤预后价值的研究进展

Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[6]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[8]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[9]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.